[1]陈思, 陈瑞. 他汀类药物在预防和治疗子痫前期中的潜在作用[J]. 中国优生与遗传杂志, 2018, 26: 115-117. [2]杨怡珂, 丁新. 妊娠期血脂的相关研究进展[J]. 医学综述, 2017, 23: 3002-3007. [3]Lu F, Bytautiene E, Tamayo E, et al. Gender-specific effect of overexpression of SFlt-1 in pregnant mice on fetal programmol/Ling of blood pressure in the offspring later in life[J]. Am J Obstet Gynecol, 2007, 197: 418.e1-e5. [4]蒋荣珍, 滕银成, 黄亚绢, 等. TLR4基因敲除对sFlt-1诱导子痫前期小鼠模型临床特征的影响[J]. 中国优生与遗传杂志, 2014, 22: 17-20+2. [5]Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia[J]. J Clin Invest, 2003, 111: 649-658. [6]Costantine MMOL/L, Cleary K. Eunice kennedy shriver national institute of child health and human development obstetric—fetal pharmacology research units network. Pravastatin for the prevention of preeclampsia in high risk pregnant women[J]. Obstet Gynecol, 2013, 121: 349-353. [7]Saad AF, Kechichian T, Yin H, et al. Effects of pravastatin on angiogenic and placental hypoxic imbalance in a mouse model of preeclampsia[J]. Reprod Sci, 2014, 21: 138-145. [8]Adu-bonsaffoh K, Antwi DA, Gyan B, et al. Endothelial dysfunction in the pathogenesis of pre-eclampsia in Ghanaian women[J]. BMC Physiol, 2017, 17: 5-12. [9]Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia[J]. N Engl J Med, 2004, 350: 672-683. [10]杨文珺, 程蔚蔚. 普伐他汀在子痫前期防治中的研究进展[J]. 复旦学报(医学版), 2016, 43: 368-372. [11]Shiota M, Hikita Y, Kawamoto Y, et al. Pravastatin-induced proangiogenic effects depend upon extracellular FGF-2[J]. J Cell Mol Med, 2012, 16: 2001-2009. [12]Torry DS, Mukherjea D, Arroyo J, et al. Expression and function of placenta growth factor: implications for abnormal placentation[J]. J Soc Gynecol Investig, 2003, 10: 178-188. [13]李红波, 苏磊, 林新峰,等. HSP27在热打击致F98细胞氧化应激损伤及细胞凋亡中的作用[J]. 解放军医学杂志, 2018, 43: 854-859. [14]沈星辉, 崔香顺, 李星炫,等. 白细胞介素-6通过IL-6/Stat3信号传导路径提升猪孤雌胚胎的体外发育[C]. 中国解剖学会2012年年会论文文摘汇编. 2012, 82. |